SEC Form 4 · accession 0000885590-15-000033

Bausch Health Companies Inc. · BHC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Administration & CHCO

Period of report

May 1, 2015

Accepted (ET)

May 5, 2015 · 4:57 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000885590

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, no par value^F2,F1	May 1, 2015	M	3,675	—	A	96,060	D
Common Stock, no par value^F3	May 1, 2015	F	1,921	$0.00	D	94,139	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2,F1	—	May 1, 2015	M	3,675	D	—	—	Common Stock	3,675	0	D

F1Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
F2This represents the number of units vested on the PSUs that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return ("TSR") between a price of $43.50 starting on December 7, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 7, 2014, 50% on December 7, 2014 and 25% on March 7, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs have now vested in full.
F3This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of performance-based RSUs.